Illumina Inc SEC Filings

Illumina, Inc. reported Q3 2025 results with total revenue of $1,084 million, essentially flat year over year ($1,080 million). Product revenue was $927 million, led by sequencing consumables at $747 million, while service and other revenue was $157 million. Net income was $150 million, or $0.98 diluted EPS. Income from operations was $227 million, reflecting higher gross margin versus last year’s mix and the absence of prior-year settlement credits.

Year to date, revenue was $3,184 million and net income reached $516 million. Cash from operations was $758 million, supporting $706 million of share repurchases (7.45 million shares) under a $1.5 billion authorization. Cash and cash equivalents were $1,050 million, short‑term investments $228 million, and term debt totaled $1,992 million (with $998 million current). The company disclosed $747 million in remaining performance obligations (77% expected within 12 months) and noted ongoing headwinds in Greater China. Illumina agreed to acquire SomaLogic and certain assets from Standard BioTools for $350 million in cash, plus up to $75 million in milestones, subject to regulatory approvals, with expected closing in the first half of 2026.

Jacob Thaysen, who is listed as Chief Executive Officer and a Director of Illumina, Inc. (ILMN), reported a sale of company stock on 10/05/2025. The filing shows 1,301 shares were disposed of at a price of $101.02 per share. After the transaction the reporting person beneficially owned 82,089 shares, held in a direct ownership form. The Form 4 was signed on 10/07/2025.

Scott B. Ullem, a director of Illumina, Inc. (ILMN), reported on Form 4 that on 09/30/2025 he acquired 252 shares of Illumina common stock issued in lieu of cash retainer fees at an implied price of $99.1666 per share. Following the transaction he beneficially owns 8,389 shares, held directly. The filing states Mr. Ullem elected to receive 100% of his 2025 board and committee cash retainer fees in Illumina stock, with share counts determined using the quarter’s volume-weighted average closing price. The form is signed on 10/02/2025.

Illumina insider Steven Barnard, SVP and Chief Technology Officer, reported a sale of 287 shares of Common Stock on 09/05/2025 at a reported price of $98.93 per share, leaving him with 33,546 shares beneficially owned after the transaction. The Form 4 was signed by Robert Maynes on behalf of Mr. Barnard on 09/09/2025. The filing lists no derivative transactions.

Capital World Investors filed an amended Schedule 13G reporting beneficial ownership of 16,866,776 Illumina shares, representing 10.7% of the 158,300,000 shares believed to be outstanding. CWI reports sole voting power over 16,802,393 shares and sole dispositive power over 16,866,776 shares, and identifies itself as a division of Capital Research and Management Company. The filing states the securities were acquired and are held in the ordinary course of business and were not acquired to change or influence control of Illumina. The filing includes the issuer address, filer address, and CUSIP 452327109.